S-Equol: a novel therapeutic for HIV-1-associated gastrointestinal dysbiosis
SE may provide a novel adjuvant treatment in addition to cART for HIV-1-associated dysbiosis and associated neurocognitive dysfunction.
Authors
- Sarah J. Olmstead (ORCID: https://orcid.org/0000-0002-1342-6022)
- Rosemarie M. Booze (ORCID: https://orcid.org/0000-0003-3908-8313)
- Charles F. Mactutus (ORCID: https://orcid.org/0000-0002-6508-1329)
- Kristen A. McLaurin (ORCID: https://orcid.org/0000-0001-7816-1806)
- Mason T. Rodriguez
Institutions
- University of South Carolina (US)
Publication Details
- Journal
- NeuroImmune Pharmacology and Therapeutics
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1515/nipt-2024-0024
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of South Carolina
- National Institutes of Health